Mesenchymal Stem Cells in Renal Ischemia-Reperfusion Injury: Biological and Therapeutic Perspectives

Author(s): Honglin Hu, Cong Zou

Journal Name: Current Stem Cell Research & Therapy

Volume 12 , Issue 3 , 2017

Become EABM
Become Reviewer
Call for Editor


Acute renal failure (ARF) is a syndrome of abrupt decline in renal function induced by a number of different insults. In clinic, the common etiology for ARF is ischemia-reperfusion injury (IRI). The pathophysiological process of renal IRI is complex, there is no good treatment. Stem cell therapy is a new and promising treatment for renal IRI. Mesenchymal stem cells (MSCs) have the ability to differentiate into tissues of mesodermal lineages. MSCs are under intensive study as potential therapeutic strategy for renal IRI. MSCs have been investigated with immunomodulatory, anti-inflammatory and tissue repair properties which could attenuate ischemic injury and accelerate the regeneration process in the condition of renal IRI. Moreover, the MSCs have the ability to migrate to the injury sites and to stimulate repair by paracrine mechanisms rather by differentiating into the injured cells. Here we review the latest information on MSCs, their biological characteristics, including their therapeutic perspectives, and envisage their putative role in renal ischaemic conditioning.

Keywords: Differentiation, immunomodulatory, ischemia-reperfusion injury, kidney, mesenchymal stem cells, paracrine.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 24 October, 2016
Page: [183 - 187]
Pages: 5
DOI: 10.2174/1574888X11666161024143640
Price: $65

Article Metrics

PDF: 61
HTML: 17